One brain implant, speech and gestures: the September 2026 study
A new ECoG study decoded speech and gestures together. What three participants, two concurrent-task participants and restricted vocabularies actually show.
Medical research
New treatments, clinical trials and what their results could mean for patients.
Intismeran melanoma vaccine: the 2026 Phase 3 results explained
What Merck and Moderna reported for intismeran (V940) plus Keytruda in INTerpath-001—and why Phase 2b percentages are not the Phase 3 result.
TRG035 tooth-regrowth drug: trial status, eligibility and availability
The verified TRG035 timeline: its initial Phase I plan, August 2026 Phase IIa notification, congenital-tooth focus and unconfirmed launch and price.
Zimislecel (VX-880): clinical results and the 2026 update
What the zimislecel study found, why the insulin-independence denominator is 12, the immunosuppression and safety context, and Vertex’s August 2026 update.
UP421 and SC451: diabetes cells without immunosuppression?
The 14-month UP421 follow-up, why its low-dose donor cells did not prove insulin independence, and how the separate SC451 candidate differs.
Speech BCI at home: what nearly two years of use demonstrated
The June 2026 home-use study explained: 3,800-plus hours, speech and cursor control, and why 92% sentence ratings differ from controlled word accuracy.
Tzield in 2026: delaying stage 3 and preserving insulin production are different uses
The June 2026 US label separates stage 2 from newly diagnosed pediatric stage 3 diabetes. Neither indication means replacing insulin-producing cells.
Otarmeni: FDA approval, hearing results and who it is for
Otarmeni’s April 2026 approval explained: OTOF eligibility, 16-of-20 hearing-sensitivity result, accelerated approval, procedure risks and remaining evidence.
Pancreatic cancer vaccine: the 2025–2026 follow-up explained
What later autogene-cevumeran reports added: persistent T cells, longer follow-up, and why seven of eight responders is not a universal survival rate.
ARC-EX: FDA clearance, home use and what the evidence shows
ARC-EX’s hand-strength and sensation indication, November 2025 home-use clearance, and the FDA’s explicit limits on functional and neurological claims.
What happened to VX-264? The discontinued diabetes cell program
Vertex discontinued VX-264 after it missed an efficacy endpoint. Why that is not the same as terminating zimislecel or disproving every immune-protection strategy.
Streaming brain-to-voice: the 2025 speech BCI result explained
The study behind near-real-time synthesized speech: streaming output, a personalized voice and why 80-millisecond increments are not an accuracy score.
Ryoncil is an FDA-approved MSC therapy. That does not approve every stem-cell claim.
What Ryoncil was approved to treat, what 38 responses among 54 treated patients means, and why unrelated regenerative-clinic claims need their own evidence.
KEYNOTE-942: what the original melanoma vaccine trial found
The original randomized Phase 2b analysis of mRNA-4157 plus pembrolizumab: recurrence results, uncertainty, adverse events and later-study distinctions.
Lantidra: the approved donor-islet therapy is not stem-cell therapy
Lantidra’s U.S. indication, donor-cell source, insulin-independence evidence and immunosuppression risks—separate from zimislecel and experimental immune-evasive cells.
Brain–spine interface walking study: a digital bridge, not regrowth
What the 2023 brain–spine interface demonstrated in one participant, how a decoded intention controlled stimulation, and what the result does not prove.
The 2023 pancreatic cancer vaccine study: what 16 patients showed
A historical account of the autogene-cevumeran Phase 1 study, its immune-response finding, combination treatment and the limits of responder comparisons.
Brain-computer interface risks: what a long-term BrainGate safety report actually showed
A 14-person historical cohort provides useful safety evidence, but 17 calendar years, aggregate implant days and individual follow-up are not interchangeable.